2025-07-15  3:11:01 PM Chg. +0.500 Volume Bid5:35:16 PM Ask5:35:16 PM Market Capitalization Dividend Y. P/E Ratio
19.500EUR +2.63% 2,146
Turnover: 41,054.199
-Bid Size: - -Ask Size: - 34.68 mill.EUR - -

Business description

Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna and has been listed in the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on patent-protected technology platforms. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as eyes, nose, lung or gastrointestinal tract. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and can reduce the risk of an infection with SARS-CoV-2. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 30 countries worldwide.
 

Management board & Supervisory board

CEO
Andreas Grassauer
Management board
Gabriele Ram, Eva Prieschl-Grassauer
Supervisory board
Simon Nebel, Elisabeth Lackner, Karl Mahler
 

Company data

Name: Marinomed Biotech AG
Address: Hovengasse 25,A-2100 Korneuburg
Phone: +43-2262-90300
Fax: -
E-mail: office@marinomed.com
Internet: https://www.marinomed.com/de/
Industry Group: Healthcare
Industry: Healthcare products
Sector: Pharmaceuticals
Subsector: Pharmaceuticals
End of financial year: 12-31
Free Float: 70.40%
IPO date: 2019-02-01

Investor relations

Name: Stephanie Kniep
IR phone: -
IR Fax: -
IR e-mail: ir@marinomed.com

Company calendar

CW 38 | 2025-09-17 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

FreeFloat
 
69.40%
Eva Prieschl-Grassauer CSO
 
7.40%
Andreas Grassauer CEO
 
7.40%
Herman Unger
 
7.00%
Mohammed Al Sheikh
 
4.40%
Abdulmohsen Al Sheikh
 
4.40%